Last reviewed · How we verify

NCT06104007: SFRGENISTA

Safety and Efficacy of Paclitaxel Coated PTCA Balloon Catheter With a Shellac Plus Vitamin E Excipient (GENOSS® DCB) in Patients With Coronary In-stent Restenosis (ISR): A Prospective, Multi-center, Observational Study

Recruiting now Last updated 27 October 2023
What this trial tests

trial testing Genoss® DCB in Coronary Artery Disease in 1,000 participants. Currently enrolling.

Timeline
17 August 2023
Primary endpoint
30 June 2028
31 December 2028

Quick facts

Lead sponsorSeoul National University Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,000
Start date17 August 2023
Primary completion30 June 2028
Estimated completion31 December 2028
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Seoul National University Hospital

Who can join

19 and older, any sex, with Coronary Artery Disease or In-stent Restenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The SFRGENISTA study aims to evaluate the long-term efficacy and safety of a paclitaxel-coated balloon catheter containing shellac and vitamin E excipients (Genoss® DCB) in patients with coronary in-stent restenosis (ISR).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Genoss® DCB

Trials testing the same drug.

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Seoul National University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06104007.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing